For research and educational purposes only. Not medical advice.

Abaloparatide Reference

Educational, not medical advice reference for Abaloparatide: Bone, Hormonal; regulatory status, evidence posture, source review, and schedule no…

Reference summary

Abaloparatide is a label-verified PTHrP analog with approved-label osteoporosis evidence. pepSmart surfaces label-reference content only and is not a prescribing tool.

Regulatory and posture

Categories
Bone, Hormonal
Aliases
Tymlos, PTHrP analog
Evidence posture
human
Regulatory status
FDA-approved prescription medication (Tymlos). Labeled for osteoporosis treatment in postmenopausal women and in men at high risk of fracture. Cumulative lifetime exposure (teriparatide plus abaloparatide) should not exceed 2 years per label.
Content review status
label verified

Selected public sources

Related tools